The Committee will discuss biologics license application (BLA) 761032, brodalumab injection, a human monoclonal antibody, submitted by Valeant Pharmaceuticals for the treatment of moderate to severe plaque psoriasis in adult patients who are can candidates for systemic therapy or phototherapy.